CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 119 enrolled
Drug / intervention
spironolactone +1 moredrug
Likely dose
spironolactone 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01062763
NCT01062763Phase 3Completed
CompareCT.gov

South Danish Hypertension and Diabetes Study

Ib Abildgaard Jacobsen·interventional·Posted Feb 4, 2010·Updated May 8, 2014

In Brief

A Phase 3 clinical trial evaluating spironolactone and placebo for Arterial Hypertension and 2 related conditions. Completed, enrolled 119 participants.

Detailed Summary

The purpose of this study is to estimate the effect of spironolactone on blood pressure resistant to therapy in type-2 diabetics.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsArterial Hypertension, Hypertension, Resistant to Conventional Therapy, Diabetes Mellitus
Countries--
Collaborators--

Timeline

Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedFeb 4, 2010
Enrollment StartMar 1, 2010
Primary CompletionMar 1, 2012
Study CompletionMay 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 16.4 years ago

Interventions

spironolactonedrug

25 to 50 mg once daily

placebodrug

addition of placebo 1 to 2 tablets daily